Standard treatment for myositis and muscular dystrophies;Therapiestandard bei myositiden und muskeldystrophien

Nervenarzt

Volumn 82, Issue 6, 2011, Pages 723-732

  Schmidt, J ^a   Vorgerd, M ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Monoclonal antibodies; Muscular dystrophy; Myositis; Neuromuscular disorders; Therapy

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

CARDIORESPIRATORY TREATMENT; CHEMOTHERAPY; CORTICOSTEROID THERAPY; DISEASE CONTROL; IMMUNOSUPPRESSIVE TREATMENT; MUSCULAR DYSTROPHY; MYOSITIS; ORTHOPEDICS; PHYSIOTHERAPY; REVIEW; THERAPY; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUSCULAR DYSTROPHIES; MYOSITIS;

EID: 79959916901     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-010-2970-3     Document Type: Review

References (29)

1. Amato AA, Barohn RJ (2009) Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry 80:1060-1068
2. Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9:77-93
3. Chung Yl, Alexanderson H, Pipitone N et al (2007) Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 57:694-702 (Pubitemid 46764062)
4. Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971-982 (Pubitemid 37159295)
5. Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993-2000 (Pubitemid 24015043)
6. Dalakas MC, Rakocevic G, Schmidt J et al (2009) Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132:1536-1544
7. Darin N, Kroksmark AK, Ahlander AC et al (2007) Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I. Eur J Paediatr Neurol 11:353-357 (Pubitemid 47534996)
8. Godfrey C, Escolar D, Brockington M et al (2006) Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol 60:603-610 (Pubitemid 44871803)
9. Greenberg SA, Pinkus Jl, Pinkus GS et al (2005) Interferon-alpha/beta- mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57:664-678 (Pubitemid 40628855)
10. Griggs RC (2006) The current status of treatment for inclusion-body myositis. Neurology 66:S30-S32
11. Group MS (2004) Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology 63:718-720
12. Jackson CE, Barohn RJ, Gronseth G et al (2008) Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 37:473-476 (Pubitemid 351501973)
13. Kirschner J, Schessl J, Schara U et al (2010) Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol 9:1053-1059
14. Kitazawa M, Trinh DN, Laferla FM (2008) Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 64:15-24
15. Kley RA, Vorgerd M, Tarnopolsky M (2007) Creatine for treating muscle disorders. Cochrane Database Syst Rev CD004760
16. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52:601-607
17. Lindberg C, Trysberg E, Tarkowski A et al (2003) Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 61:260-262 (Pubitemid 36875317)
18. Lunemann JD, Schmidt J, Schmid D et al (2007) Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 61:476-483 (Pubitemid 46878775)
19. Malik V, Rodino-Klapac LR, Viollet L et al (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 67:771-780
20. Mendell JR, Rodino-Klapac L, Rosales X et al (2010) Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol 68:629-638
21. Miller FW, Leitman SF, Cronin ME et al (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326:1380-1384
22. Mok C, Ho L, To C (2007) Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 34:1864-1868 (Pubitemid 350067647)
23. Schmidt J, Barthel K, Wrede A et al (2008) Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 131:1228-1240
24. Schmidt J, Dalakas M (2010) Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opin Med Diagn 4:241-250
25. Somani A, Swick A, Cooper K et al (2008) Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 144:1341-1349
26. Sveen Ml, Jeppesen T, Hauerslev S et al (2007) Endurance training: an effective and safe treatment for patients with LGMD2I. Neurology 68:59-61 (Pubitemid 46058554)
27. Tawil R, Van Der Maarel S, Padberg G et al (2010) 171st ENMC international workshop: standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord 20:471-475
28. van Deutekom J, Janson A, Ginjaar I et al (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677-2686
29. Wong-Kisiel L, Kuntz N (2010) Two siblings with limb-girdle muscular dystrophy type 2E responsive to deflazacort. Neuromuscul Disord 20:122-124